Drug Evaluation, Preclinical; Oncology; Radiobiology; Radiochemistry; Radiopharmaceuticals
- Ludwig Boltzmann Institute Applied Diagnostics
Research Area: The focus of the institute lies on the development of non-invasive diagnostic methods linking molecular epigenetic and genetic signatures with molecular imaging biomarkers for PET and SPECT analysis. The combination of these two methods will allow for improved functional, spatial and temporal assessment of tumor load and molecular tumor characterization.
My main research interest lies in (targeted) radiotherapy of cancer, including novel approaches of Auger Electron Therapy. In this context, I currently focus on therapeutic efficacy studies in 2D and 3D cell culture systems.
- Balber, T.; Tran, L.; Benčurová, K.; Raitanen, J.; Egger, G.; Mitterhauser, M. Experimental Nuclear Medicine Meets Tumor Biology. Pharmaceuticals 2022, 15, 227. https://doi.org/10.3390/ph15020227
- Bamminger, K. et al. (2022) ‘Rapid, high-yield enzymatic synthesis of n.c.a. 6-[18F]fluorodopamine (6-[18F]FDA) for in vivo application’, Nuclear Medicine and Biology [Preprint]. Available at: http://dx.doi.org/10.1016/j.nucmedbio.2022.07.001